H.R. 7667: Food and Drug Amendments of 2022
CBO Report Details
Legislation Details
117th Congress
To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.
Sponsor: Rep. Anna Eshoo — D — CA
Reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices. Specifically, the bill reauthorizes through FY2027 the FDA user fee programs for prescription drugs, medical devices, generic drugs, and biosimilars. The bill also requires the development of action plans...
JOIN US!
Sign up below to receive updates when your Members of Congress vote for new spending increases or cuts.
Lost your Password?
Don't be sad- we've got your back. Just enter your email below and instructions on resetting your password will be sent to you.
×